Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | April 03, 2023 | April 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date April 03, 2023 · Filed April 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby CLAT | 125,493 |
Reported balance
After 2023-04-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-04-03 · Gift · Disposed 259 · Balance 125,493 |
| Common StockSEC Table I · non-derivative | Direct | 312,578 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 312,578 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,963 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,963 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse as Trustee | 23,461 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 23,461 |
| Common StockSEC Table I · non-derivative | Indirectby trust for grandch | 3,609 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,609 F1: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust. |
Filing footnotes · ownership attribution and instrument terms
F1: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8,622 | $603.54 | $5,203,721.88 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 11 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 60,376 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 8,622 shares of Company stock on August 11, 2020 at prices ranging from $603.00 to $603.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,769 | $602.66 | $2,271,425.54 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 10 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 68,998 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 3,769 shares of Company stock on August 11, 2020 at prices ranging from $602.05 to $602.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,281 | $601.42 | $1,973,259.02 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 9 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 72,767 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 3,281 shares of Company stock on August 11, 2020 at prices ranging from $601.00 to $601.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,851 | $600.30 | $2,912,055.30 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 8 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 76,048 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 4,851 shares of Company stock on August 11, 2020 at prices ranging from $600.00 to $600.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 718 | $599.37 | $430,347.66 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 7 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 80,899 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 718 shares of Company stock on August 11, 2020 at prices ranging from $599.01 to $599.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 843 | $598.52 | $504,552.36 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 81,617 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 843 shares of Company stock on August 11, 2020 at prices ranging from $598.04 to $598.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 950 | $597.74 | $567,853.00 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 82,460 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 950 shares of Company stock on August 11, 2020 at prices ranging from $597.40 to $597.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 162 | $595.69 | $96,501.78 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 83,410 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 162 shares of Company stock on August 11, 2020 at prices ranging from $595.00 to $595.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 80 | $594.20 | $47,536.00 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 83,572 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 06, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 341 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 143,559 Read SEC document |
| May 27, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 73,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,649 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $578.34 | $57,834.00 |
DisclosureSEC source: 0001708138-20-000062 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,749 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 683 | $577.37 | $394,343.71 |
DisclosureSEC source: 0001708138-20-000062 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,849 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 683 shares of Company stock on May 21, 2020 at prices ranging from $577.08 to $577.51. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 206 | $576.47 | $118,752.82 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 30 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,532 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F22 · price: Represents volume-weighted average price of sales of 206 shares of Company stock on May 21, 2020 at prices ranging from $576.25 to $576.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. F23 · balance_after: Form one of two Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,606 | $575.34 | $1,499,336.04 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 29 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,738 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F21 · price: Represents volume-weighted average price of sales of 2,606 shares of Company stock on May 21, 2020 at prices ranging from $575.00 to $575.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,622 | $574.69 | $1,506,837.18 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 28 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,344 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F20 · price: Represents volume-weighted average price of sales of 2,622 shares of Company stock on May 21, 2020 at prices ranging from $574.13 to $574.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,610 | $573.55 | $1,496,965.50 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 27 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,966 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F19 · price: Represents volume-weighted average price of sales of 2,610 shares of Company stock on May 21, 2020 at prices ranging from $573.26 to $573.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,356 | $572.69 | $776,567.64 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 26 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,576 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F18 · price: Represents volume-weighted average price of sales of 1,356 shares of Company stock on May 21, 2020 at prices ranging from $572.20 to $572.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,877 | $571.32 | $1,643,687.64 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 25 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,932 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F17 · price: Represents volume-weighted average price of sales of 2,877 shares of Company stock on May 21, 2020 at prices ranging from $571.01 to $571.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,049 | $570.60 | $1,169,159.40 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 24 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,809 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · price: Represents volume-weighted average price of sales of 2,049 shares of Company stock on May 21, 2020 at prices ranging from $570.01 to $570.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,232 | $569.40 | $1,840,300.80 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 23 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,858 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · price: Represents volume-weighted average price of sales of 3,232 shares of Company stock on May 21, 2020 at prices ranging from $569.00 to $569.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11,447 | $568.43 | $6,506,818.21 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 22 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,090 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 11,447 shares of Company stock on May 21, 2020 at prices ranging from $568.00 to $568.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9,138 | $567.51 | $5,185,906.38 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 21 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,537 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 9,138 shares of Company stock on May 21, 2020 at prices ranging from $567.00 to $567.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14,548 | $566.42 | $8,240,278.16 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 20 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,675 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 14,548 shares of Company stock on May 21, 2020 at prices ranging from $566.00 to $566.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12,996 | $565.47 | $7,348,848.12 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 19 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,223 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 12,996 shares of Company stock on May 21, 2020 at prices ranging from $565.00 to $565.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 13,268 | $564.62 | $7,491,378.16 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 18 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,219 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 13,268 shares of Company stock on May 21, 2020 at prices ranging from $564.00 to $564.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11,551 | $563.53 | $6,509,335.03 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 17 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,487 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 11,551 shares of Company stock on May 21, 2020 at prices ranging from $563.00 to $563.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8,359 | $562.48 | $4,701,770.32 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 16 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,038 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 8,359 shares of Company stock on May 21, 2020 at prices ranging from $562.00 to $562.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10,418 | $561.40 | $5,848,665.20 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 15 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,397 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 10,418 shares of Company stock on May 21, 2020 at prices ranging from $561.00 to $561.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12,456 | $560.45 | $6,980,965.20 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 14 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,815 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 12,456 shares of Company stock on May 21, 2020 at prices ranging from $560.00 to $560.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8,826 | $559.51 | $4,938,235.26 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 13 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,271 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 8,826 shares of Company stock on May 21, 2020 at prices ranging from $559.01 to $559.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11,168 | $558.36 | $6,235,764.48 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 12 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,097 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 11,168 shares of Company stock on May 21, 2020 at prices ranging from $558.00 to $558.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,910 | $557.51 | $3,294,884.10 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 11 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,265 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 5,910 shares of Company stock on May 21, 2020 at prices ranging from $557.02 to $557.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,168 | $556.79 | $650,330.72 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 10 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,175 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 1,168 shares of Company stock on May 21, 2020 at prices ranging from $556.59 to $556.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 77,309 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-20-000062 · edgardoc.xml · derivative · entry 12 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,309 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. F5 · balance_after: Form two of two Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 77,309 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-20-000062 · edgardoc.xml · derivative · entry 11 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,309 Underlying: Common Stock · 77,309 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 77,309 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-20-000062 · edgardoc.xml · derivative · entry 10 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,618 Underlying: Common Stock · 77,309 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 77,309 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-20-000062 · edgardoc.xml · derivative · entry 9 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,927 Underlying: Common Stock · 77,309 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,264 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-20-000062 · edgardoc.xml · derivative · entry 8 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,264 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 39,720 | $570.97 | $22,678,928.40 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 9 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,343 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 77,309 | $30.63 | $2,367,974.67 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 8 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 497,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 39,974 | $570.97 | $22,823,954.78 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 7 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,754 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 77,309 | $30.63 | $2,367,974.67 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 39,974 | $570.97 | $22,823,954.78 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,419 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 77,309 | $30.63 | $2,367,974.67 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,393 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 39,974 | $570.97 | $22,823,954.78 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,084 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 77,309 | $30.63 | $2,367,974.67 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,264 | $30.63 | $99,976.32 |
DisclosureSEC source: 0001708138-20-000061 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 02, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 433 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000062 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 143,900 Read SEC document |
| January 03, 2020 Filed May 22, 2020 22:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 564 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000062 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 144,333 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.